They also investigated a new strategy to significantly
inhibit glioma growth by rationally combining gemcitabine and MK - 8776, a cell cycle checkpoint inhibitor.
«The treatment with gemcitabine and MK - 8776 to
inhibit glioma growth is a promising strategy that warrants further investigation,» said Khan.
Not exact matches
«Our study suggests that ALDH1A3 is a potentially functional biomarker for mesenchymal
glioma stem cells, and that
inhibiting that enzyme might offer a promising therapeutic approach for high - grade
gliomas that have a mesenchymal signature,» says principal investigator Ichiro Nakano, MD, PhD, associate professor of neurosurgery at the OSUCCC — James.
Inhibiting ALDH1A3 - mediated pathways slows the growth of mesenchymal
glioma stem cells and might provide a promising therapeutic approach for glioblastomas with a mesenchymal signature.
They will follow this approach to design a novel treatment plan by rationally combining gemcitabine with cell cycle checkpoint inhibitor, oxygen - enrich gas inhalation, and radiotherapy to significantly
inhibit the growth of aggressive
glioma.
Block of purinergic P2X7R
inhibits tumor growth in a c6
glioma brain tumor animal model.
These findings have therapeutic implications since
inhibiting MBD2 could offer a strategy to reactivate BAI1 and suppress
glioma pathobiology, â $ the authors write.